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Background: Increased tumor size is a known risk for poor 
outcomes in patients with stage I and II non–small cell lung 
cancer (NSCLC), who are treated with surgery or radio-
therapy. However, there is limited information regarding the 
impact of tumor size on the outcomes of patients with medias-
tinal lymph node involvement. We conducted a Surveillance, 
Epidemiology, and End Results (SEER) database analysis to 
evaluate the prognostic significance of tumor size in patients 
with unresected stage III NSCLC.
Methods: The SEER registry was queried for patients with 
unresected NSCLC stage III and no malignant pleural effu-
sion, aged 21 years or older, and diagnosed between 1998 
and 2003. Tumor size was defined as S1 (0.1–3 cm), S2 
(3.1–5 cm), S3 (5.1–7 cm), and S4 (7.1–20 cm). Demographic 
variables included age, sex, race and histology. Overall sur-
vival (OS) and disease-specific survival (DSS) were estimated 
by the Kaplan–Meier method, and the Cox proportional haz-
ard model was used to evaluate whether tumor size remained 
an independent risk factor in multivariable analysis.
Results: A total of 12,315 patients met the eligibility criteria. 
Median age at diagnosis was 70 years and most patients were 
men (58.7%) and white (81.3%). Tumor size was an indepen-
dent predictor for both OS (p < 0.0001) and DSS (p < 0.001) 
in all subgroups of patients.
Conclusion: Tumor size is an independent predictor for OS 
and DSS in patients with unresected stage III NSCLC, and 
should be considered in the stratification of patients treated in 
this setting after validation of this finding in additional studies.
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Among patients with non–small-cell lung cancer (NSCLC), approximately 27% present with locally advanced disease 
according to the American Joint Commission on Cancer (AJCC) 
6th edition.1 The current proportion of patients presenting with 
stage III disease is actually lower than prior estimates, partly 
because of the reclassification of malignant pleural effusion, 
as stage IV disease according to the updated staging system, 
and because of stage migration resulting from improved diag-
nostic imaging modalities.2,3 Patients with locally advanced 
NSCLC caused by mediastinal involvement are rarely candi-
dates for surgical resection and approximately 25% are cured 
with concurrent chemoradiation. Given the heterogeneous 
nature of locally advanced NSCLC, it is imperative to identify 
and validate clinical and molecular predictors of outcomes so 
that patients considered to be at high risk for relapse can be 
selected for additional investigations and therapies.
Tumor size is a known prognostic factor for patients with 
resected NSCLC and more recent studies revealed significant 
differences in outcomes even with smaller increases in tumor 
size, leading to further classification of patients previously cate-
gorized to have stage I into four different subgroups and upstag-
ing of tumors larger than 7 cm to stage III.4–6 Similar findings 
have been observed in patients with stage I disease, who are inel-
igible for surgery and treated with definitive radiotherapy. In a 
review of 18 studies from 1988 to 2000 involving 1680 patients 
with unresected stage I NSCLC, most studies reported improved 
local control and survival in patients with smaller tumors defined 
variably as less than 4 cm or stage IA.7 In the Cochrane review of 
26 nonrandomized trials, evaluating the role of radiation therapy 
in 2003 patients with stage I or II disease, who were deemed 
inoperable or declined surgery, survival was better in patients 
with T1 tumors compared with patients with T2 tumors and was 
inversely proportional to the tumor size.8
Because tumor size significantly affects outcomes in 
patients with early-stage NSCLC, we conducted a database 
survey to evaluate its prognostic impact in patients with 
locally advanced disease.
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MATERIALS AND METHODS
We searched the SEER-17 registry data for patients with 
stage III NSCLC caused by N2 or N3 disease, aged 21 years 
or older, with active follow-up, and diagnosed between 1998 
and 2003. Stage III was defined by the AJCC codes 31 (IIIA) 
and 32 (IIIB). Lymph nodes were classified according to the 
extent of disease (EOD) codes 2 (N2) or 6 (N3). Pleural effu-
sion (EOD code 72) was excluded because patients with pleu-
ral effusion are usually treated as having metastatic disease, 
and its presence now defines stage M1a according to the new 
staging system.
The histology was coded according to the International 
Classification of Diseases for Oncology (ICD-0–3) into adeno-
carcinoma (8140–8147, 8255, 8260, 8310, 8323, 8480, 8481, 
8490, 8550, 8572), squamous cell carcinoma (8050–8052, 
8070–8078), large-cell carcinoma (8012, 8014), and other his-
tologies, including undifferentiated tumors (8020–8022) and 
carcinomas not otherwise specified (NOS), or not defined as 
one of the three most common histologies (8010, 8015, 8030, 
8036). Bronchioloalveolar carcinoma and large-cell neuroen-
docrine carcinomas were excluded.
Demographic variables were defined as age at diagnosis, 
sex, and race (white, black, and other). Tumor size was defined 
as S1 (0.1–3 cm), S2 (3.1–5 cm), S3 (5.1–7 cm), and S4 (7.1–
20 cm), reflecting the new AJCC staging classification.6
Statistical Analysis
Overall survival (OS) was defined as time from diag-
nosis to death from any cause, and patients alive were cen-
sored at the time of last recording. OS and disease-specific 
survival (DSS) among different tumor size groups were esti-
mated using the Kaplan–Meier product method and compared 
by log-rank test. The effect of tumor size was also assessed 
by multivariable Cox proportional hazard model, after adjust-
ing for age, race, sex, histology, and stage. All statistical tests 
were two-sided and p value less than 0.05 was considered to 
be significant. Statistical analyses were performed using the 
standard package SAS (version 9.1, SAS Institute, Cary, NC).
RESULTS
Demographics
The cohort was composed of 12,315 patients who met 
the inclusion criteria, including 6327 (51.4%) with stage IIIA 
and 5,988 (48.6%) with stage IIIB. Demographics character-
istics are described in Table 1. Median age at diagnosis was 
70 years (range, 24–99). Most patients were men (58.7%) 
and white (81.3%). The histologic distribution included 3500 
patients (28.4%) with adenocarcinoma, 3920 (31.8%) with 
squamous cell carcinoma, 768 (6.24%) with large-cell carci-
noma, and 4127 (33.5%) with other histologies. The median 
tumor size was 4.5 cm (range, 0.11–20 cm). The median fol-
low-up duration was 10 months (range, 0–94 months).
Univariate Survival Analysis
Both OS and DSS were better in patients with stage 
IIIA compared with those with stage IIIB (Table 2). However, 
selected categories of stage IIIB with smaller tumors had 
improved OS and DSS compared with patients with stage 
IIIA and larger tumors. In addition to stage and size, several 
other variables were also associated with worse OS and DSS, 
including age, sex, race, and histology (Table 3).
The risk of death from any cause increased significantly 
with each size category for both stages, ranging from 13% to 
15% in stage IIIA and 9% to 11% in stage IIIB (Table 4, Figs. 
1 and 2). Similar findings were observed in the risk of death 
from lung cancer, where each size category increased the risk 
by 16% to 19% in patients with stage IIIA and by 10% to 13% 
in those with stage IIIB.
Multivariable Survival Analysis
Tumor size was a statistically significant predictor for 
both OS (p < 0.0001) and DSS (p < 0.0001) on multivariable 
analysis adjusting for age, race, sex, and histology (Table 5). 
There was a significant increase in the risk of death from any 
cause between adjacent tumor-size categories, ranging from 
11% between IIIAS1 and IIIAS2 to 14% between IIIAS2 and 
IIIAS3 or IIIAS3 and IIIAS4. This effect was more signifi-
cant in the risk of lung cancer death, which increased by 17%, 
19%, and 18% from IIIAS1 to IIIAS2, IIIAS2 to IIIAS3, and 
IIIAS3 to IIIAS4, respectively.
Similar findings were observed in patients with stage 
IIIB, in whom the risk of death increased by 9% from IIIBS1 
to IIIBS2, 11% from IIIBS2 to IIIBS3, and 10% from IIIBS3 
to IIIBS4 with corresponding increases in risk of death from 
lung cancer of 11%, 11%, and 12%, respectively.
To further evaluate the value of tumor size as a prognos-
tic factor and compare it with N stage subsets, the established 
prognostic factor in stage III NSCLC, we performed two addi-
tional multivariable analyses (data not shown). The first analysis 
included age, sex, race, histology, lymph node status, and tumor 
size while excluding AJCC stage, whereas the second had all 
the previous factors with the addition of stage. N3 was associ-
ated with worse OS (hazards ratio [HR] 1.077; 95% confidence 
TABLE 1. Patient Demographics
Parameter Variable N %
Sex Female 5082 41.3
Male 7233 58.7
Race White 10,004 81.3
African American 1493 12.1
Other 805 6.5
Histology Adenocarcinoma 3500 28.4
Squamous 3920 31.8
Large cell 768 6.24
Other 4127 33.5
Size of tumor (cm) S1 (0.1–3) 3499 28.4
S2 (3.1–5) 4245 34.5
S3 (5.1–7) 2645 21.5
S4 (7.1–20) 1926 15.6
Stage IIIA 6327 51.4
IIIB 5988 48.6
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interval [CI] 1.023–1.13; p = 0.005) and DSS (HR 1.096; 
95%CI 1.037–1.159; p = 0.001) compared with N2, when 
stage was excluded. However, neither OS (HR 0.99; 95%CI 
0.93–1.05, p = 0.84) nor DSS (HR 099; 95%CI 0.93–1.06; p = 
0.98) were decreased in patients with N3 when AJCC stage was 
included in the analysis. In contrast, OS and DSS were signifi-
cantly decreased with each tumor-size category in both models.
DISCUSSION
Stage III is a heterogeneous disease ranging from surgi-
cally resectable T3N1 to unresectable T4N3. Although most 
patients with mediastinal or supraclavicular lymph node 
involvement are treated with chemoradiotherapy, there are sev-
eral prognostic factors unaccounted for in the stratification for 
the clinical trials. In our study, we showed a significant impact 
for tumor size in the outcomes of unresected patients with N2 
or N3 disease. These results are not surprising, because tumor 
size has been previously associated with outcomes in both sur-
gical and nonsurgical patients with early-stage disease.
Retrospective analyses of large cooperative trials have 
identified several factors associated with worse outcomes 
in patients with stage III NSCLC, including baseline forced 
expiratory volume in 1 second of 2 L or less and hemoglobin 
lesser than 12 g/dL in the Hoosier Oncology Group LUN 
01-24 study, comorbidity with Charlson scale of more than 
2 or Cumulative Illness Rating Scale for Geriatrics positive, 
and Karnofsky performance score (KPS) of 70 or less in the 
evaluation of Radiation Therapy Oncology Group trials 8311, 
8403, 8407, and 8808.9,10 In the Cancer and Leukemia Group B 
39801 trial, which compared induction chemotherapy followed 
by chemoradiotherapy with chemoradiotherapy alone, the four 
independent factors for worse survival were age of 70 years or 
more, hemoglobin less than 13 g/dL, weight loss by 5% or more, 
and KPS 1.11 Median survivals for patients with none, one, 
two or more than two factors were 24 months, 18 months, 10 
months, and 8 months, respectively. Tumor size larger than 7 cm 
was not associated with worse survival in univariate analysis in 
the combined Radiation Therapy Oncology Group trials.10
Recent studies have evaluated the impact of tumor vol-
ume in the survival of stage III patients treated with chemo-
radiotherapy. De Petris et al.12 described lymph node status 
N3 and gross tumor volume higher than 100 cm3 as inde-
pendent predictors for worse survival in 32 patients treated 
with chemoradiotherapy. Basaki et al.13 found a significant 
decrease in OS for patients with gross tumor volume higher 
than the median of 85 cm3. Alexander et al.14 found that nodal 
and tumor volumes were independent predictors for OS in 76 
patients treated with definitive chemoradiotherapy. Tumor vol-
ume was also associated with worse survival in patients with 
stage I to III undergoing definitive radiation with or without 
chemotherapy.15–17 Although the majority of studies have used 
tumor volume instead of size, data regarding tumor volume are 
not available in the SEER database. Similarly, despite intui-
tive assumption that larger tumor volumes could be associated 
with worse outcomes, the major randomized clinical trials for 
locally advanced NSCLC did not include either tumor size or 
volume in the demographic characteristics.18–23
Our study has several limitations that are inherent to any 
retrospective study of large centralized databases. Prognostic 
factors previously described such as hemoglobin, KPS, and forced 
TABLE 2. Overall Survival and Disease-Specific Survival (DSS) According to Stage and Tumor Size
Stage Tumor Size Median Survival (Mos) 1 Yr (%) 2 Yrs (%) 3 Yrs (%) 4 Yrs (%) 5 Yrs (%)
Overall survival
 IIIA All sizes 11 43.8 21.9 13.5 9.2 6.9
S1 13 50.3 27.7 17.1 11.7 8.6
S2 11 43.9 22.4 13.2 9.2 7.2
S3 9 38.9 16.5 11.3 8.3 5.6
S4 8 35.2 14.5 9.1 4.6 3.7
 IIIB All sizes 9 38.3 17.9 10.4 7.8 6.0
S1 11 43.8 22.4 13.3 9.9 8.3
S2 10 40.1 18.7 10.0 7.2 4.9
S3 9 35.1 15.4 9.3 7.4 5.7
S4 8 31.6 13.6 8.7 6.3 5.4
Disease-specific survival
 IIIA All sizes 12 49.5 27.1 18.3 13.5 11.0
S1 15 57.0 34.7 23.6 18.1 14.5
S2 12 49.9 27.6 18.0 13.5 11.5
S3 10 43.8 20.5 14.8 11.2 8.0
S4 9 38.9 17.8 11.4 6.1 5.4
 IIIB All sizes 11 42.9 22.0 13.8 10.9 9.0
S1 12 48.9 27.2 17.5 13.8 11.7
S2 11 44.7 22.8 13.3 10.3 7.7
S3 10 39.9 19.4 12.2 10.6 8.6
S4 8 35.3 16.9 11.4 8.6 8.0
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expiratory volume in 1 second are not reported in the SEER 
database and were not included in this analysis. Tumor volume, 
lymph node size, and information regarding chemotherapy are 
also not reported to the SEER database. Furthermore, there 
seems to be a lack of adequate histological definition because 
approximately one third of the patients had NSCLC NOS, a 
finding that has been also observed in a more recent SEER 
analysis, where the percentage of patients diagnosed with NOS 
histology increased from 15.8% in the 1989–1994 period to 22% 
and 29% in the 1995–2000 and 2000–2006 periods, respectively, 
being more common in elderly and stage IV patients diagnosed 
cytologically.24 Nevertheless, this large study provides an 
TABLE 4. Risk of Death According to Tumor Size and Stage
Parameter
Overall Survival Disease-Specific Survival
HR 95% CI p HR 95% CI p
IIIAS1 vs. IIIAS2 1.13 1.06–1.21 0.0001 1.18 1.10–1.27 < 0.0001
IIIAS2 vs. IIIAS3 1.15 1.07–1.023 0.0002 1.19 1.10–1.28 < 0.0001
IIIAS3 vs. IIIAS4 1.13 1.03–1.24 0.0009 1.16 1.05–1.27 0.003
IIIBS1 vs. IIIBS2 1.11 1.03–1.19 0.0004 1.13 1.04–1.22 0.002
IIIBS2 vs. IIIBS3 1.10 1.02–1.18 0.0009 1.10 1.02–1.18 0.01
IIIBS3 vs. IIIBS4 1.09 1.004–1.18 0.04 1.11 1.02–1.22 0.01
S1, 0–3 cm; S2, 3.1–5 cm; S3, 5.1–7 cm; S4, 7.1–20 cm.
CI, confidence interval; HR, hazard ratio.
TABLE 3. Univariate Analysis for Overall Survival and Disease-Specific Survival
Variable
Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Overall Survival p Disease-Specific Survival p
Age (yrs)
21–60 1.0 0.0003 1.0 0.014
61–70 1.1 (1.04–1.16) < 0.001 1.07 (1.01–1.13) < 0.001
71–80 1.43 (1.36–1.50) < 0.001 1.34 (1.27–1.41) < 0.001
80–101 1.68 (1.58–1.79) 1.57 (1.46–1.68)
Sex
Female 1.0 < 0.001 1.0 < 0.001
Male 1.16 (1.12–1.21) 1.14 (1.10–1.19)
Race
White 1.0 0.21 1.0
Black 0.96 (0.91–1.02) < 0.001 0.96 (0.90–1.02)
Other 0.85 (0.79–0.92) 0.81 (0.75–0.89)
Histology
Sqauamous 1.0 < 0.001 1.0 < 0.001
Adenocarcinoma 0.82 (0.78–0.86) 0.70 0.83 (0.79–0.87) 0.985
Large cell 0.98 (0.90–1.07) 0.019 0.99 (0.91–1.08) 0.002
Other 0.94 (0.90–0.99) 0.92 (0.88–0.97)
N status
N2 1.0 0.83 1.0 0.68
N3 0.99 (0.94–1.05) 1.01 (0.95–1.06)
Tumor size (cm)
S1 (0.1–3) 1.0 < 0.001 1.0 < 0.001
S2 (3.1–5) 1.13 (1.08–1.18) < 0.001 1.16 (1.10–1.22) < 0.001
S3 (5.1–7) 1.27 (1.21–1.34) < 0.001 1.33 (1.26–1.41) < 0.001
S4 (7.1–20) 1.41 (1.33–1.50) 1.51 (1.42–1.61)
AJCC stage
IIIA 1.0 < 0.001 1.0 < 0.001
IIIB 1.12 (1.08–1.16) 1.15 (1.11–1.20)
CI, confidence interval; AJCC, American Joint Commission on Cancer.
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indication that tumor size may be a significant prognostic factor in 
unresected stage III NSCLC, similarly to what has been observed 
in patients with earlier stages. If this finding is confirmed in 
prospective studies, stratification of treatment groups according 
to tumor size may be warranted in future trials involving the use 
of chemoradiotherapy for patients with locally advanced NSCLC.
TABLE 5. Multivariable Analysis for Overall Survival and Disease-Specific Survival According to Tumor Size
Overall Survival Disease-Specific Survival
Parameter HR 95% CI p HR 95% CI p
IIIAS1 vs. IIIAS2 1.11 1.04–1.19 0.001 1.17 1.09–1.25 < 0.0001
IIIAS2 vs. IIIAS3 1.15 1.07–1.24 0.0001 1.19 1.10–1.29 < 0.0001
IIIAS3 vs. IIIAS4 1.15 1.05–1.26 0.002 1.18 1.07–1.30 0.001
IIIBS1 vs. IIIBS2 1.09 1.01–1.19 0.02 1.11 1.03–1.20 0.007
IIIBS2 vs. IIIBS3 1.11 1.04–1.20 0.003 1.11 1.03–1.20 0.007
IIIBS3 vs. IIIBS4 1.10 1.01–1.19 0.02 1.12 1.03–1.22 0.01
S1, 0–3 cm; S2, 3.1–5 cm; S3, 5.1–7 cm; S4, 7.1–20 cm.
CI, confidence interval; HR, hazard ratio.
FIGURE 1. OS for patients with stages IIIA (1A) and IIIB (1B) 
according to tumor size. OS, overall survival.
FIGURE 2. DSS for patients with stages IIIA (2A) and IIIB 
(2B) according to tumor size. DSS, disease-specific survival.
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